Rats bite a Phase III study

Rats bite a Phase III study Long-term preclinical toxicology data have forced Bristol-Myers Squibb Co. to suspend Phase III trials of its lobucavir nucleoside analog to treat chronic hepatitis B and herpes viruses.

The preliminary data from long-term rodent studies of lobucavir indicated a potential drug-related increase in tumors. Bristol-Myers consequently suspended dosing and patient accrual until the data and its implications are fully reviewed.

While a potential link to cancer

Read the full 830 word article

How to gain access

Continue reading with a
two-week free trial.